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Abstract
Cancer ’omics datasets involve widely varying sizes and scales, measurement vari-
ables, and correlation structures. An overarching scientific goal in cancer research is
the development of general statistical techniques that can cleanly sift the signal from
the noise in identifying genomic signatures of the disease across a set of experimental
or biological conditions. We propose BayesDiff, a nonparametric Bayesian approach
based on a novel class of first order mixture models, called the Sticky Poisson-Dirichlet
process or multicuisine restaurant franchise. The BayesDiff methodology flexibly uti-
lizes information from all the measurements and adaptively accommodates any serial
dependence in the data, accounting for the inter-probe distances, to perform simulta-
neous inferences on the variables. The technique is applied to analyze the motivating
DNA methylation gastrointestinal cancer dataset, which displays both serial correla-
tions and complex interaction patterns. In simulation studies, we demonstrate the
effectiveness of the BayesDiff procedure relative to existing techniques for differential
DNA methylation. Returning to the motivating dataset, we detect the genomic sig-
nature for four types of upper gastrointestinal cancer. The analysis results support
and complement known features of DNA methylation as well as gene association with
gastrointestinal cancer.
Keywords: Genomic signature; First order models; Mixture models; Multicuisine restaurant
franchise; Sticky Poisson-Dirichlet process
1 Introduction
Recent advances in array-based and next-generation sequencing (NGS) technologies have
revolutionized biomedical research, especially in cancer. The rapid decline in the cost of
genome technologies enables the measurement of genomic activity at a very detailed resolu-
tion and provides genome-wide information at the transcriptomic (e.g., gene/mRNA expres-
sion), genomic (e.g., copy number variation), epigenomic (e.g., methylation), and proteomic
levels on matched patient or tissue samples (Hamid et al. 2009). These datasets involve
intrinsically different sizes and scales of high throughput data, providing genome-wide, high
resolution information about the biology of cancer.
A common goal is the identification of differential genomic signatures between samples
corresponding to different treatments or biological conditions, e.g., treatment arms, response
to adjuvant chemotherapy, tumor subtypes, or cancer stages. The analytic challenges in-
clude the high dimensionality of genomic markers such as genes and probes, usually in the
hundreds of thousands, and the relatively small number of patient samples, usually no more
than a few hundred. This “small n, large p” problem results in unstable inferences due to
collinearity. There also exist complex interaction patterns, such as signaling or functional
pathway-based interactions for gene or protein expression data, and genomic or chromoso-
1
mal location-based serial correlation for high-throughput sequencing data. These interaction
patterns can significantly influence the reliable detection of differential genomic signatures.
Differential DNA Methylation in Gastrointestinal Cancer
DNA methylation is a vitally important epigenetic mechanism that occurs by the addition
of a methyl (CH3) group to DNA, resulting in the modification of the gene functions. This
typically occurs at specific genomic locations called cytosine-phosphate-guanine (CpG) sites.
Alterations in DNA methylation, e.g., hypomethylation of oncogenes and hypermethylation
of tumor suppressor genes (Feinberg & Tycko (2004)), are often associated with the devel-
opment and progression of cancer. It was previously believed that these alterations almost
exclusively occur in specific promoter regions known as CpG islands, which are chromosomal
regions with a high frequency of CpG sites. However, with the advent of high-throughput
technologies, it has been shown that a significant proportion of methylation alterations in
cancer do not occur in either promoters or CpG islands (Irizarry et al. 2009), prompting
higher resolution, epigenome-wide investigations.
Gastrointestinal (GI) cancer, the most common form of cancer in the U.S. (Siegel et al.
2017), refers to malignant conditions affecting the digestive system. This includes cancers
of the esophagus, gallbladder, liver, pancreas, stomach, small intestine, bowel and anus. In
the motivating application, we focused on four types of GI cancers related to the upper
digestive tract: stomach adenocarcinoma (STAD), liver hepatocellular carcinoma (LIHC),
esophageal carcinoma (ESCA) and pancreatic adenocarcinoma (PAAD). Epigenetic alter-
ations are usually observed in these types of GI cancer (Vedeld et al. 2017). For example,
infections involving Helicobacter pylori and Epstein-Barr virus, two major risk factors for
stomach cancer, are associated with increased levels of promoter DNA methylation (Maekita
et al. 2006, Graham 2015, Network et al. 2014). Hypermethylation of the gene CDKN2A is
often present in large contiguous fields of ESCA samples (Eads et al. 2000). Molecular char-
acterization of the cancer types, facilitated by the identification of differentially methylated
sites, is therefore key to gaining a better understanding of GI cancer.
In this paper, we analyze methylation profiles publicly available from The Cancer Genome
Atlas (TCGA) project, with 50 randomly selected tumor samples from each of the four GI
cancer types. For 485,577 probes, DNA methylation levels ranging from 0 (no methylation)
to 1 (full methylation) were measured using the Illumina Human Methylation 450 platform,
with each probe mapped to one CpG site. The left panel of Figure 1 displays the methylation
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Figure 1: Exploratory analysis of CpG sites near gene TP53 for the motivating gastroin-
testinal cancer data. See the text for further explanation.
levels for CpG sites near TP53, a tumor suppressor gene located on chromosome 17. The col-
ors represent the different cancer types. Although differential methylation is clearly visible
in some CpG sites, the differences are generally subtle and hard to distinguish, demonstrat-
ing the need for sophisticated statistical analyses. A common feature of DNA methylation
data is the correlation between the methylation status of nearby CpG sites (Eckhardt et al.
2006, Irizarry et al. 2008, Leek et al. 2010). This can be seen in the right panel of Figure
1, which reveals fairly high first order autocorrelations for the neighboring sites, along with
a highly significant overall test for serial correlations. Additionally, the high variability of
the inter-probe spacings suggests that distance-based dependencies would provide a better
fit to the data.
Existing statistical approaches Numerous frequentist and Bayesian methods have been
developed for differential DNA methylation. Existing approaches can be broadly classi-
fied into four categories: (i) Testing-based methods, such as Illumina Methylation Analyzer
(IMA) (Wang et al. 2012), City of Hope CpG Island Analysis Pipeline (COHCAP) (Warden
et al. 2013), and BSmooth (Hansen et al. 2012). These methods rely on two-sample or
multiple-sample tests for the difference in means at each CpG site. (ii) Regression based
models, such as Methylkit (Akalin et al. 2012), bump hunting (Jaffe et al. 2012), Biseq (Hebe-
streit et al. 2013), and RADMeth (Dolzhenko & Smith 2014). After applying smoothing
or other adjustments, these methods fit individual regression models for each CpG site and
test for significance. (iii) Beta-binomial model-based methods, such as MOABS (Sun et al.
3
2014), DSS (Feng et al. 2014), and methylSig (Park et al. 2014). These methods fit separate
models for each CpG site based on the beta-binomial distribution and detect differential
CpG sites via the estimated model parameters. (iv) Hidden Markov models (HMMs), such
as MethPipe (Song et al. 2013), Bisulfighter (Saito et al. 2014), and HMM-DM (Yu & Sun
2016). These methods rely on HMMs to model the methylation data for the entire genome
and detect differentially methylated sites based on the inferred hidden states.
The aforementioned methods, although effective, have some important shortcomings.
For instance, most methods ignore the strong correlations between neighboring CpG sites.
The non-HMM methods fit separate models to each CpG site, thereby reducing the detection
power due to the small sample sizes. The beta-binomial, HMM, and most of the testing-
based methods are able to accommodate only two treatments or groups. To handle multiple
treatments, they typically resort to low-power multiple comparison adjustments.
Among methods capable of accounting for serial dependence (e.g., HMMs), a common
drawback is that they fail to adjust for the widely varying distances between the CpG
sites. That is, irrespective of the distances between neighboring sites, these methods assume
that the inter-site dependencies are uniform. However, empirical evidence (e.g., see Figure 1)
strongly suggests that the dependencies decrease with increasing distance. The few methods
that do account for inter-site distances (e.g., Hansen et al. 2012, Jaffe et al. 2012, Hebestreit
et al. 2013) often rely on ad hoc procedures to determine their tuning parameters, such as
bandwidths, and do not adequately adjust for the unique characteristics of the datasets.
We have found that the serial correlation of the methylation levels is often significantly
weaker than that of the differential state categories (differentially versus non-differentially
methylated) of the CpG sites. This is reasonable because the former condition implies
the latter. Consequently, first order techniques that primarily model the correlation of the
methylation levels could be ignoring important information about the underlying correlation
structure. Finally, most methods have been specially developed for a particular data type
(e.g., either DNA methylation arrays or bisulfite sequencing data), and are not applicable
to differently sized and scaled data (e.g., gene or mRNA expression data).
This paper proposes general and flexible methodology for differential analysis, referred to
as BayesDiff. Rather than fitting a separate model for each genomic locus or probe, Bayes-
Diff relies on a global framework for simultaneous inferences on the probes and is capable
of adapting to the distinctive features of ’omics datasets. A set of probe-specific differen-
tial state variables delineates the genomic signature of the disease, and is a deterministic
4
function of a set of latent random effects vectors.
To diminish collinearity effects and achieve dimension reduction in the large number of
probes, we allocate the probes to a smaller, unknown number of latent clusters based on
similarities in their multivariate random effects. We devise a novel extension of Poisson
Dirichlet processes (PDPs) (Perman et al. 1992) called the Sticky PDP (or, equivalently,
the multicuisine restaurant franchise) for modeling the allocation mechanism. In addition
to accounting for long range biological interactions between non-adjacent probes, the non-
parametric stochastic process accommodates distance-based serial dependences between the
probes. The correlation strength is determined by a univariate dependence parameter that
is learned from the data. For example, the correlation can be chosen to be zero in datasets
lacking serial dependence. Furthermore, the model permits the data to direct the choice
between PDPs, and their special case, Dirichlet processes, in finding the best-fitting alloca-
tion scheme. The methodology is applicable to differential analysis in genomic, epigenomic,
transcriptomic, and proteomic datasets.
We implement a fully Bayesian inferential procedure using a Markov chain Monte Carlo
(MCMC) algorithm specifically developed for posterior inferences in Sticky PDPs. The
MCMC strategy is scalable to the ubiquitous big datasets in cancer research. Bayesian
false discovery rate (FDR) control is implemented for multiplicity adjustment. Simulation
results show that our approach significantly outperforms existing methods for multigroup
comparisons in datasets with or without serial correlation. For the motivating GI cancer
data, in addition to confirming known features of DNA methylation and gene associations
with cancer, the analysis revealed interesting facts about the biological mechanisms of the
four cancer types.
The rest of the paper is organized as follows. Section 2 describes the BayesDiff model
and the construction of the Sticky PDP or multicuisine restaurant franchise. The MCMC
algorithm and related inference procedures are outlined in Section 3. For various scenarios,
Section 4 uses artificially generated datasets to evaluate the accuracy of BayesDiff in detect-
ing disease genomic signatures. The motivating GI dataset is analyzed using the BayesDiff
procedure in Section 5. Conclusions and possible extensions to the BayesDiff approach are
discussed in Section 6.
5
2 The BayesDiff Model
Assume that we have continuous, proportion, or count measurements on p biomarkers such as
genes or CpG sites (“probes”), and on n matched patient or tissue samples (“individuals”),
with p being much larger than n. The data are arranged in an n× p matrix, X = ((xij)) for
individuals i and probes j, with the probes sequentially indexed by their genomic locations.
The distances between the adjacent probes are denoted by e1, . . . , ep−1, and usually have
a significant amount of variability. In the GI cancer dataset, the DNA methylation levels
belong to the interval [0, 1], and the inter-probe distances range from 2 base pairs to more
than 1, 141K base pairs.
Each individual i is associated with an experimental or biological condition (“treat-
ment”), with treatment label ti taking values in the set {1, ..., T} for some T ≥ 2. In the
motivating application, T = 4 because we consider four GI cancer types. We make a suitably
chosen platform-specific transformation z(·), and define zij = z (xij). For count data x ∈ N,
an appropriate transformation could be z(x) = log (1 + x). For proportion data 0 < x < 1,
the logit function, z(x) = log (x/ (1− x)) may be appropriate. For continuous data x ∈ R,
we could simply choose the identity transformation. We assume that
zij = z (xij) ∼ N
(
ξi + θtij, σ
2
)
(1)
where ξi represents the ith subject-specific random effect and θtj is the random effect asso-
ciated with the treatment t–probe j combination. We further decompose parameter ξi into
interpretable deterministic and stochastic components:
ξi = bi + i, (2)
where bi is a known (possibly zero) individual-specific constant and i represents the residual
individual variability, which is assumed to be iid normal: i
iid∼ N (0, τ 2 ). We impose inverse-
Gamma priors on the variance parameters σ2 and τ 2 .
The primary analytical goal is the detection of differential probes. In the context of our
model, these are the probes whose treatment-specific effects are not all identical. Inference
therefore focuses on the vector of treatment-specific random effects, θj = (θ1j, . . . , θTj)
′, for
probe j = 1, . . . , p. We define a binary differential state variable, sj, with the value sj = 1
indicating that probe j is not differential, and value sj = 2 indicating that it is differential.
6
More specifically,
sj =
1 if θ1j = θ2j = · · · = θTj,2 otherwise, (3)
for j = 1, . . . , p. The disease genomic signature consists of the probes with state sj = 2.
The key parameters of interest are therefore the differential state variables, s1, . . . , sp. We
assume flexible Bayesian nonparametric models for random effects θ1, . . . ,θp, as discussed
below.
Modeling the probe clusters
In addition to high-dimensionality, the analytical challenges posed by cancer datasets in-
clude pervasive collinearity caused by dependencies between physically proximal probes and
dependencies due to longer range biological interactions between non-adjacent probes, e.g.,
through signaling or functional pathway-based interactions (Guha & Baladandayuthapani
2016). Collinearity is known to cause inaccuracies in estimation and uncertainty quantifica-
tion. To mitigate the effects of collinearity and extract information from the large number
of probes through dimension reduction, we allocate the p probes to a much smaller number,
q, of latent clusters based on the similarities in the probe-specific random effects θj. We
favor clustering to unsupervised dimension reduction methods such as principal components
analysis because our findings have direct biological interpretation in terms of potentially
relevant biomarkers.
Suppose that an allocation variable, cj, assigns probe j to one of q latent clusters, where
q is unknown. The event [cj = k] implies that the j
th probe belongs to the kth cluster,
k = 1, . . . , q. The q clusters are assumed to be associated with latent vectors, φ1, . . . ,φq,
each vector of length T . The probe-specific random effects and cluster-specific latent vectors
have the relation
θj = φk if cj = k. (4)
In other words, all probes assigned to a cluster have identical random effects equal to that
cluster’s latent vector. The probes’ differential state variables, defined in equation (3), are
then attributes of their parent clusters, and the clusters as a whole are either differential or
non-differential. The condition θ1j = θ2j = · · · = θTj in equation (3) is equivalent to the
condition φ1k = φ2k = · · · = φTk if probe j belongs to cluster k (i.e., if cj = k). We represent
7
the set of differential clusters as
D =
{
k : φtk 6= φt′k, for some t 6= t
′
, k = 1, . . . , q
}
Mixture models for allocations Bayesian infinite mixture models are a natural choice
for allocating p probes to a smaller, unknown number of latent clusters based on the simi-
larities in their random effects. Dirichlet processes Ferguson (1973) are the most frequently
used infinite mixture models; see Mu¨ller & Mitra (2013, chap. 4) for a comprehensive re-
view. The use of Dirichlet processes to achieve dimension reduction in massive datasets has
precedence in the literature (see Medvedovic et al. 2004, Kim et al. 2006, Dunson et al.
2008, Dunson & Park 2008, Guha & Baladandayuthapani 2016). Lijoi, Mena & Pru¨nster
(2007a) advocated the use of Gibbs-type priors (Gnedin & Pitman 2005, Lijoi, Mena &
Pru¨nster 2007b) for accommodating more flexible clustering mechanisms. In particular, (Li-
joi et al. 2007a) demonstrated the utility of Poisson-Dirichlet processes (PDPs) in genomic
applications. Guha & Baladandayuthapani (2016) introduced PDP-based clustering, vari-
able selection, and prediction techniques for high-dimensional regression, demonstrating that
PDPs are overwhelmingly favored to Dirichlet processes for fitting gene expression cancer
datasets.
The two-parameter PDP (Perman et al. (1992)) relies on a discount parameter d ∈
[0, 1), positive mass parameter α, and T -variate base distribution W , and is denoted by
W(d, α,W ). The value d = 0 yields a Dirichlet process with mass parameter α and
base distribution W . Suppose the sequence of random effects θ1, . . . ,θp are distributed
as W(d, α,W ). The stick-breaking representation of the PDP is θj iid∼ P , where random
distribution P is the discrete mixture ∑∞v=1 piv1φv , with 1φv denoting a point mass located
at the atom φv
iid∼ W . The random stick-breaking probabilities have the form: pi1 = V1 and
pih = Vh
∏h−1
v=1(1− Vv) for h > 1, where Vh
indep∼ beta(1− d, α + hd).
Although the aforementioned techniques achieve dimension reduction in the large number
of probes and account for long range biological interactions between non-adjacent probes,
a potential drawback is their implicit assumption of apriori probe exchangeability. Con-
sequently, they are unable to account for serial correlation between the probes. Infinite
HMMs, such as the hierarchical Dirichlet process hidden Markov model (HDP-HMM) (Teh
et al. 2006) and Sticky HDP-HMM (Fox et al. 2011) may be utilized to fill this gap. In these
models, each probe j has an associated group depending on the preceding probe’s random
effect, θj−1. The group, in turn, determines the distribution of random effect θj, inducing
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first order dependence between the random effects.
Infinite HMMs are a step in the right direction, but they have some undesirable features
for cancer data analysis. First, the degree of first order dependence is uniform irrespective
of the inter-probe distances. This is unrealistic in epigenomic datasets where the correlation
between adjacent probes typically decreases with the distance (Hansen et al. 2012, Jaffe
et al. 2012, Hebestreit et al. 2013). Second, the set of distinct random effects is potentially
infinite and has a bijective mapping with the set of groups, which is therefore also infinite.
In contrast, an ad hoc exploratory analysis of the GI cancer dataset reveals that the serial
correlation in the random effects vectors, although significant, is much weaker than the serial
dependence between the binary state variables defined in equation (3). This suggests that a
hypothetical two-group Markov model, rather than an infinite-group Markov model such as
HPD-HMM or Sticky HDP-HMM, would provide a much better fit for the data. Third, the
range of allocation patterns supported by infinite HMMs is relatively limited. In particular,
patterns such as power law decays in the cluster sizes and large numbers of small-sized
clusters, a common feature of cancer datasets, are assigned small aprior probabilities by
infinite HMMs.
For these reasons, we propose a novel extension of PDPs called the Sticky PDP, capable
of accommodating distance-based serial dependences between the probes and allowing far
fewer groups than random effects clusters. Furthermore, the data can direct the choice
between appropriate extensions of PDPs and Dirichlet processes nested within the model in
order to find the best-fitting allocation pattern.
2.1 The Sticky PDP
Informally, a Sticky PDP is a cohort of regular PDPs that generates the probe-specific
random effects, θ1, . . . ,θp, by switching the generative PDPs at random locations along
the probe sequence. We formally define the most general form of Sticky PDPs. Section 2.2
introduces the multicuisine franchise presentation of a Sticky PDP. Later, in Section 2.3, the
process is customized to the differential analysis of multiple treatments in cancer research.
The Sticky PDP is characterized by the following general properties:
Property 1: Let set G contain a countable number of generative groups. Each group g ∈ G contains
a countable number of group-specific, regular PDPs. The PDPs are identified by a
combination of the group label g and an integer-valued state, s ∈ S ⊂ N , the set of
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natural numbers. That is, the regular PDPs comprising a Sticky PDP have bivariate
labels, (g, s) ∈ G × S.
Property 2: The regular PDPs may have equal or unequal discount parameters, mass parameters,
and/or base distributions. For every (g, s) ∈ G × S, let the corresponding PDP be
Wgs(ds, αs,Ws). With Pgs denoting a random realization of the PDP’s stick-breaking
distribution, we have
Pgs d=
∞∑
v=1
pigsv1φgsv where the T -variate atoms
φgsv
iid∼ Ws, for index v ∈ N , and probabilities (5)
pigs1 = Vgs1, pigsh = Vgsh
h−1∏
v=1
(1− Vgsv), h > 1, with
Vgsh
indep∼ beta(1− ds, αs + hds).
Notice that base distribution Ws in RT is determined by the state s but not group
g. On the other hand, the atoms and their associated probabilities in distribution Pgs
may depend on the group and the state.
If set S contains multiple states, assume that the set of base distributions {Ws : s ∈ S}
is such that two PDPs associated with unequal states will almost surely have non-
intersecting sets of atoms. That is, whenever s∗1 6= s∗2, the intersection of the random
sets of the atoms {φg∗1s∗1v}∞v=1 and {φg∗2s∗2v}∞v=1 of stick-breaking distributions Pg∗1s∗1 and
Pg∗2s∗2 is almost surely empty.
Property 3: For probe j = 1, . . . , p, the label of the PDP generating random effect θj is denoted
by (gj, sj) ∈ G ×S, and θj | gj, sj ∼ Pgjsj . Equivalently, random effect θj equals atom
φgjsjvj with probability pigjsjvj for index vj ∈ N .
Property 4: Given group gj for the j
th probe, the state of the PDP generating random effect θj is
randomly selected as follows:
sj | gj ∼ Qgj
where for every g ∈ G, Qg denotes a group-specific probability mass function on the
set S; thus, ∑s∈S Qg(s) = 1.
Property 5: (Markov property) For probe j > 1, given the variables associated with the preceding
probes, group variable gj has a mass function depending on random vector θj−1 and
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Model G Wgs(ds, αs,Ws) Pgs Fθ,e
HDP-HMM N Wg(0, α,W ),
∑∞
v=1 pigv1φv Point mass at
countably infinite W
∑∞
v=1 v · I(θ = φv)
Finite HMM {1, . . . ,K} Wg(0, α,W ),
∑K
v=1 pigv1φv Point mass at
discrete W with K <∞ atoms ∑Kv=1 v · I(θ = φv)
HDP {1, . . . ,K} Wg(0, α,W ),
∑∞
v=1 pigv1φv 1{g},
countably infinite W prespecified g ∈ G
PDP {1} W(d, α,W ) ∑∞v=1 piv1φv 1{1}
Dirichlet process {1} W(0, α,W ) ∑∞v=1 piv1φv 1{1}
Finite mixture {1} W(0, α,W ), ∑Kv=1 piv1φv 1{1}
discrete W with K <∞ atoms
Table 1: Examples of Sticky PDPs. Set N represents the natural numbers. All the above
examples correspond to singleton set S = {1} and degenerate distribution Qg = 1{1}. Refer
to the text for the notation.
inter-probe distance ej−1:
gj ∼ Fθj−1,ej−1
where, for every θ ∈ RT and e > 0, Fθ,e denotes a probability mass function on the
set G, so that ∑g∈G Fθ,e(g) = 1. For the first probe, group g1 follows a categorical
distribution, F0, on the set G.
In addition to extending PDPs to discrete time series type data, Sticky PDPs offer a
diverse palette of parametric and nonparametric models for capturing the distinctive fea-
tures of different datasets. The range of models includes Dirichlet processes, PDPs, infinite
HMMs, hierarchical Dirichlet process (HDP) (Mu¨ller et al. (2004), Teh et al. (2006)), fi-
nite HMMs, nested Chinese restaurant processes (Blei & Jordan (2005)), nested Dirichlet
processes (Rodriguez et al. (2008)), and analysis of densities models (Tomlinson & Escobar
(2003)). Some examples are presented in Table 1. As suggested by the form of distribution
Fθ,e in Table 1, the first two examples are first-order models and the remaining examples
are zero-order models. The Sticky PDP can be equivalently described by the following
representation.
2.2 Multicuisine Restaurant Franchise Representation
The well-known Chinese restaurant franchise (CRF) metaphor for HDP-HMMs and Sticky
HDP-HMMs (e.g., Fox et al. 2011) can be generalized to the multicuisine restaurant franchise
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(MRF) to describe Sticky PDPs. The MRF comprises several restaurants, representing
the groups g, indexed by the set G. Each restaurant is partitioned into separate sections,
representing the states s, with each section exclusively offering a cuisine indexed by the set S.
Regular PDPs, indexed by (g, s) ∈ G×S, are represented by restaurant-cuisine combinations
in the metaphor.
A succession of customers, representing the p probes, arrive at the times e0, (e0+e1), (e0+
e1 + e2), . . . ,
∑p
j=1 ej−1, representing the probe locations along a path. Each section in
every restaurant has an infinite number of tables, representing the atoms indexed v ∈ N
in expression (5), at which the customers could potentially sit. All customers seated at a
table are served the same cuisine-specific dish. Although multiple tables within a restaurant
section may serve the same dish, the cuisines are uniquely identified by their dishes because
no dish is common to two or more cuisines.
At time e0, Customer 1 randomly selects restaurant g1 ∼ F0, and proceeds to the section
serving cuisine s1 with a restaurant-specific probability of Qg1(s1). Among the infinite tables
within that section, Customer 1 chooses table v1 with cuisine-specific probability pig1s1v1 , and
is served the table-specific dish, φg1s1v1 . The dish eaten by Customer 1 is recorded as the
random effect θ1 = φg1s1v1 .
After a waiting time of e1, Customer 2 randomly selects restaurant g2 ∼ Fθ1,e1 , a decision
that depends on the dish that the previous customer had eaten and on waiting time e1. At
restaurant g2, Customer 2 chooses cuisine/section s2 with restaurant-specific probability
Qg2(s2). Customer 2 selects table v2 in this section with cuisine-specific probability pig2s2v2
and is served the table-specific dish, φg2s2v2 . The outcome is recorded as the random effect
θ2 = φg2s2v2 . This process continues for the subsequent franchise customers. Although each
restaurant offers all cuisines and serves every dish, the popularity of the cuisines and dishes
are restaurant-specific.
2.3 Sticky PDPs for Differential Analysis
We tailor Sticky PDPs to model the BayesDiff probe allocations for differential analysis
of multiple treatments. In addition to achieving dimension reduction in the large number
of probes and accounting for long range interactions between non-adjacent probes, Sticky
PDPs provide a framework for directly modeling the serial dependence between the latent
differential status of adjacent probes as a decreasing function of inter-probe distance.
The MRF metaphor can be used to broadly describe how these features are incorporated
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into the model. The franchise has two restaurants, each consisting of two sections serving
different cuisines. Section 1 in both the restaurants exclusively caters to Cuisine 1, repre-
senting the non-differential state, and therefore serves dishes identified by T -variate atoms
having all equal elements for the treatment effects. Similarly, Section 2 in both the restau-
rants exclusively caters to Cuisine 2, representing the differential state, and its dishes are
identified by atoms having at least two unequal elements. Restaurant 1 specializes in Cuisine
1, and so, that cuisine is much more popular with its customers. Similarly, Restaurant 2
specializes in Cuisine 2.
The restaurant that a customer randomly chooses is influenced by the cuisine chosen
by the previous customer. If the previous customer had eaten a dish belonging to Cuisine
1 (2), then the next customer is more likely to visit Restaurant 1 (2), where that cuisine
is more popular. In this manner, a customer is more likely to select the same cuisine as
the previous customer. Applied to the motivating GI cancer data analysis, this feature
accounts for long runs of differentially or non-differentially methylated states of the probes.
However, the preceding customer’s influence also diminishes as the time interval separating
the two customers increases. That is, the differential status of any two adjacent probes are
statistically independent in the limit as the inter-probe distance grows.
Within each restaurant section, there are an infinite number of tables. The customer’s
choice is positively reinforced by the relative popularity of the already-occupied tables in the
restaurant section. Alternatively, a customer may decide to sit at a previously unoccupied
table. All customers at a table are served the same dish, randomly selected from the cuisine-
specific menu. For the differential analysis of large cancer datasets, this offers a useful
dimension-reduction device because the latent PDP clusters, previously defined in expression
(4), correspond to the distinct restaurant–cuisine–table combinations, and are therefore far
fewer than the number of probes (i.e., franchise customers).
More formally, adapting the general Properties 1–5 of Sections 2.1 to the differential
analysis problem:
Property 1: The groups G and states S in the BayesDiff model are both equal to {1, 2}, with the set
elements representing, respectively, the non-differential and differential state. The four
regular PDPs comprising the Sticky PDP are indexed by (g, s) ∈ {1, 2} × {1, 2}. In
the MRF metaphor, there are two restaurants (i.e., groups), each serving two cuisines
(i.e., states), with Cuisine 1(2) representing the non-differential (differential) state.
Each restaurant specializes in the cuisine having the same label as the restaurant.
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Property 2: The PDPs comprising the non-differential and differential states are modeled as fol-
lows.
Non-differential state Consider state (cuisine) s = 1, corresponding to the non-
differential state. The two associated PDPs (restaurant–cuisine combinations) have
the form
Wg1(d1, α1,W1), g = 1, 2. (6)
Each T -variate atom in these PDPs has all equal elements because the non-differential
state corresponds to identical treatment effects. That is, for positive integer v, atom
φv = ψv1, where ψv ∈ R and 1 is the column vector of T ones. Since the φv are iid
draws from the base distribution W1, we have
W1
d
= ψ1, where ψ ∈ R with
ψ ∼ G, and
G ∼ DP (β,G0) ,
a Dirichlet process prior with mass parameter β and univariate base distribution,
G0 = N (µG, τ
2
G). Appropriate priors are assumed for mass parameters α1 and β. The
hyperparameters µG and τ
2
G are given conjugate priors.
The nonparametric prior for distribution G provides model flexibility. The stick-
breaking representation of the Dirichlet process implies that random distribution G is
almost surely discrete; specifically, it has the mass function
G(ψ) =
∞∑
v=1
$v1ζv(ψ) for ψ ∈ R, where
∞∑
v=1
$v = 1 and ζv
iid∼ G0. (7)
The discreteness of G is important because it results in the base distribution W1 being
discrete, thereby allowing the two regular PDPs of the non-differential state to choose
from the same countable set of atoms. In the MRF metaphor, this allows the two
restaurants to offer identical menus for Cuisine 1.
The additional flexibility of allocation provided by PDPs, relative to Dirichlet pro-
cesses, is not necessary for the non-differential states because the latent allocation
patterns associated with real numbers are anyway unidentifiable (e.g., see Fru¨hwirth-
Schnatter 2006). For this reason, we set PDP discount parameter d1 = 0, reducing
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the two non-differential state PDPs in equation (6) to Dirichlet processes.
Differential state Now consider state (cuisine) s = 2, corresponding to the dif-
ferential state. The two associated PDPs (restaurant–cuisine combinations) have the
expression Wg2(d2, α2,W2), g = 1, 2. The common T -variate base distribution, W2,
from which the differential PDPs’ atoms are drawn, must satisfy two conditions: (i)
for all positive integers v, the atom φv = (φ1v, . . . , φTv) must have at least two un-
equal elements, corresponding to the treatments effects for the differential state, and
(ii) similar to the non-differential case, the base distribution should be discrete so
that the two differential state PDPs share the same set of atoms. This allows the
two restaurants in the MRF metaphor to have identical Cuisine 2 menus. Using mass
function G of equation (7), the mass function of a T -variate base distribution W2 sat-
isfying conditions (i) and (ii) is constructed as follows. For every φ = (φ1, . . . , φT )
′,
let
W2(φ) =

∏T
t=1G(φt)/
(
1−∑∞v=1$Tv ) if φt 6= φt′ for some t 6= t′,
0 otherwise.
(8)
Base distribution W2 is discrete because distribution G is discrete. The differential
and non-differential states communicate through the common distribution G, facili-
tating the borrowing of information across the states. Furthermore, the discreteness
of distribution G results in additional dimension reduction in the differential atoms.
This feature is especially useful when the number of treatments, T , is large; it allows
several treatments within an atom to have equal values, resulting in a relatively small
number of distinct atom elements.
Unlike the non-differential situation, for the differential state, each atom element is
approximately independently distributed as the discrete distributionG when T is large.
This results in the allocation patterns of the differential probes being detectable with
high accuracy as T grows. For a detailed discussion of this remarkable phenomenon in
the context of regular PDPs, refer to (Guha & Baladandayuthapani 2016, Section 4).
Since the data are highly informative about the allocations of the differential probes,
discount parameter d2 is given the mixture prior:
d2 ∼ 1
2
1{0} +
1
2
U(0, 1)
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where 1{0} denotes a point mass at 0 and corresponds to a Dirichlet process. The
data can then flexibly choose between a Dirichlet process and a more general PDP
for a suitable clustering mechanism. For example, probe allocation patterns that are
characteristic of non-Dirichlet PDPs, such as power law decays in the cluster sizes and
relatively large numbers of small-sized clusters, would cause the posterior inferences
for parameter d2 to exclude the value of 0. On the other hand, allocation patterns
that are more typical of Dirichlet processes, such as exponentially decaying cluster
sizes dominated by a few large clusters, would result in high posterior probabilities
being assigned to the value 0. A proof of the intrinsically different allocation patterns
of Dirichlet process and PDP priors is given in (Guha & Baladandayuthapani 2016,
Theorem 2.1).
It should emphasized that since W2 is a discrete base distribution in RT , the atoms of
the differential PDP clusters, being iid W2, may not all be unique. In the MRF analogy,
this corresponds to two tables at a restaurant section serving the same dish. This is
indeed a fairly common phenomenon when the number of treatments, T = 2. However,
the assumed form of mass function (8) has an interesting effect when T is large. Using
a similar argument as that presented in Section 2.3 of Guha & Baladandayuthapani
(2016) for a different stochastic process, it can be shown that the probability that two
atoms are identical, rapidly decays to 0 as T grows, provided p grows at a slower-than-
exponential rate as T . We have verified this in our simulation studies. For example,
for p = 1, 500 probes and T as small as four, no two atoms were identical in any of
our artificial datasets.
Property 3: In general, let a realization of a PDP’s stick-breaking distribution be denoted by Pgs,
where g, s = 1, 2. For probe j = 1, . . . , p, the label of the PDP generating random
effect θj = (θ1j, . . . , θTj)
′ is denoted by (gj, sj) where gj, sj ∈ {1, 2}. Consequently,
θj | gj, sj ∼ Pgjsj d=
∑∞
v=1 pigjsjv1φgjsjv . Thus, random effect θj = φgjsjvj with proba-
bility pigjsjvj , for positive integer vj indexing the atom.
Property 4: Given group gj ∈ {1, 2} of the jth probe, the state-specific PDP generating random
effect θj is distributed as sj | gj ∼ Qgj . For g ∈ {1, 2}, mass function Qg is defined as
follows. Let parameter ρ ∈ (0, 1) be the baseline differential proportion and ρ′ = 1− ρ
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be the baseline non-differential proportion. We let
Qg(1) =
ρ
′ + ργ, g = 1
ρ′ − ρ′γ, g = 2
(9)
and Qg(2) = 1−Qg(1), where 0 < γ ≤ 1 is the group purity parameter. We assume the
independent uniform priors: ρ, γ ∼ U(0, 1). This guarantees that the non-differential
and differential group respectively favors the non-differential and differential state
relative to their baseline proportion. In the MRF analogy, each restaurant specializes
in the cuisine having the same label, and the specialty cuisine is more popular there.
Property 5: For the first probe, we assume group variable g1 ∼ F0 d= 1 + Bernoulli(ρ), where the
probability parameter ρ has been defined in Property 4.
For the subsequent probes indexed by j > 1, recall that in Sticky PDPs, the state sj−1
is always a deterministic function of random effect θj−1. (In the MRF metaphor, the
dishes uniquely identify their respective cuisines.) Consequently, we assume that the
group
gj ∼ Fθj−1,ej−1 = F∗sj−1,ej−1 (10)
for some distribution F∗. Now suppose that the scaled distance, ej−1, between the
(j − 1)th and jth probes, is transformed to an affiliation measure:
rj = exp(−ej−1/η), j > 1, (11)
whenever range parameter η > 0. When η = 0, we define affiliation rj = 0. Thus, the
affiliation rj ∈ [0, 1). Since the affiliation in equation (11) is unchanged if the distance
ej−1 and parameter η are equally scaled, we may assume without loss of generality
that the inter-probe distances e1, . . . , ep−1 are scaled so that their sum equals 1. For
example, if the probes represent biomarkers on a chromosome and the first probe is
located near the chromosomal edge, then after scaling the standardized chromosome
length is approximately equal to 1.
For every state s ∈ {1, 2}, scaled distance e ∈ (0, 1), group purity parameter γ ∈ [0, 1)
defined in Property 4, and affiliation r = exp(−e/η), we define the mass function in
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expression (10) as follows:
F∗s,e(1) =
ρ
′ + ρr/γ, s = 1
ρ′ − ρ′r/γ, s = 2
(12)
and F∗s,e(2) = 1−F∗s,e(1). If η > 0, then the serial dependencies decrease with increas-
ing inter-probe distances. Large values of η correspond to high serial dependencies.
The limiting value of η = 0 (equivalently, r = 0) corresponds to no serial dependence
between the probes. In order for expression (12) to represent a valid mass function,
it is necessary and sufficient that r/γ < 1 for every 0 < e < 1. Since the standard-
ized inter-probe distances satisfy e < 1, it can be shown that a sufficient condition is
η < −1/ log γ.
Posterior inferences on parameter η are of interest because its value determines the
degree of serial dependencies between the probes. Subject to the afore-mentioned
sufficient condition, we assume a mixture prior for parameter η:
η | γ ∼ 1
2
1{0} +
1
2
IG(1,
1
p− 1) · I(η < −1/ log γ)
The parameters of the truncated inverse-gamma distribution follow from the constraint
that, when the inter-probe distance e is equal to the mean distance of 1
p−1
∑p
j=2 ej−1 =1/(p−
1), the aforementioned prior induces an objective (that is, uniform on its support) prior
for the affiliation, r = exp(−e/η).
Equations (9) and (12) imply that
P (sj = s | sj−1 = s) =
ρ
′ + ρrj, s = 1
ρ+ ρ′rj, s = 2
(13)
Relation (13) suggests that each probe in the sequence has a relatively high probability
of persisting in the same state as the previous probe, with the degree of persistence
increasing with affiliation, i.e., small inter-probe distances and/or large values of η.
Typical investigations, in which the differential state is relatively rare, correspond to
ρ < ρ′ (i.e., ρ < 1/2). In that case, equation (13) further implies that the degree of
persistence is lower for the differential state, s = 2.
Figure 2 displays a directed acyclic graph illustrating the relationships among the Bayes-
18
Group and state model
PDP with nested DP model
Individual effects model
η αs ds β
ej−1 rj Wgs Ws G
ρ gj φgsv vj µG, τ
2
G
γ sj θj
xj zj ξi i
σ2 bi τ
2

Figure 2: Directed acyclic graph of the BayesDiff model showing the relationship among
the model components. Solid rectangles represent the data and model parameters. Dashed
rectangles represent predetermined model constants. Solid arrows represent stochastic rela-
tionships, and dashed arrows represent deterministic relationships.
Diff model components.
Relationship with PDP latent clusters The general cluster allocation, specified earlier
in expression (4), is related to the Sticky PDP as follows. We inspect the set of Sticky PDP
group–state–atom labels that are actually allocated to the p probes. That is, we inspect the
set
C =
{
(gj, sj, vj) : j = 1, . . . , p
}
Each distinct triplet belonging to the set represent a unique PDP cluster. Let set C∗ be the
set of distinct triplets belonging to the set C. The cardinality of set C∗ is then equal to the
number of PDP latent clusters, q. An arbitrary bijective mapping from the set C∗ to the set
{1, . . . , q} gives the allocation variables, c1, . . . , cp for the probes, and the relabeled Sticky
PDP atoms are the PDP latent vectors, φ1, . . . ,φq, appearing in expression (4).
3 Posterior Inferences
Due to the complexity of the BayesDiff model, we apply MCMC methods to implement a
fully Bayesian approach for posterior inference.
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3.1 Outline of the MCMC procedure
We iteratively update the BayesDiff model parameters by the following procedure:
1. Group variables g1, . . . , gp, state variables s1, . . . , sp, and cluster variables v1, . . . , vp
are sequentially sampled from their full conditionals. From these values, we compute
the allocation variables c1, . . . , cp and the total number of PDP clusters, q.
2. The latent vectors φ, consisting of Tq latent vector elements, are sampled conditional
on the current probe cluster allocations, the other model parameters, and the data.
For s = 1, 2, let qs be the total number of latent clusters allocated to the probes for
PDPs associated with state s, irrespective of the groups. Since each latent vector in
the non-differential PDPs clusters has just one unique element, this implies the number
of distinct latent vector elements is (q1 + Tq2). Due to the intensive nature of these
Gibbs sampling updates, we apply the data squashing algorithm of Guha (2010) to
speed up the computations.
3. Hyperparameters such as range parameter η, differential PDP discount parameter d2,
univariate Dirichlet process mass parameter β, base distribution hyperparameters, as
well as other model parameters such as variance parameter σ2, are sequentially sampled
from their full conditional distributions via standard MCMC methods.
Further details are provided in the Supplementary Materials.
3.2 Detection of Differential Probes with FDR Control
The primary inferential goal is, of course, the detection of differential probes. For probe
j, this information is encapsulated in the event [sj = 2]. As an optional inferential step, a
Bayesian approach for controlling the false discovery rate (FDR) (Newton et al. 2004) could
be applied for more accurately detecting the differential probes.
Specifically, let q0 be the desired FDR level and ωj be the posterior probability of probe j
being differential, so that ωj = P [sj = 2 |X]. An empirical average estimate, ωˆj, is available
from the MCMC sample. To achieve the desired FDR level in calling the differential probes,
we first rank all the probes in decreasing order of ωˆj. Let ωˆ(1) > ωˆ(2) > · · · > ωˆ(p) denote
the ordered posterior probability estimates. For each b = 1, . . . , p, we calculate the posterior
20
expected FDR resulting from calling the first b probes in decreasing order of ωˆj, as follows:
F̂DRb =
∑p
j=1 (1− ωˆj) I
(
ωˆj ≥ ωˆ(b)
)∑p
j=1 I
(
ωˆj ≥ ωˆ(b)
) = ∑bj=1 (1− ωˆ(j))
b
(14)
where the simplified expression follows from the fact that the ωˆj’s are sorted. Finally, we
pick the largest value of b, denoted by b∗, for which F̂DRb < q0. The detection rule that
labels as differential the first b∗ probes arranged in decreasing order of ωˆj, achieves the
desired FDR level.
4 Simulation Studies
To evaluate the ability of the BayesDiff procedure to detect the differential probes and learn
the underlying dependence structure of DNA methylation data, we analyzed artificially
generated datasets with multiple treatments. The accuracy of BayesDiff was compared
with those of some well-known differential methylation procedures and general statistical
techniques for multigroup comparisons.
Generation strategy Continuous data were simulated from the Section 2 model with
the identity transformation in equation (1), so that xij = zij. Later, when applying existing
methods designed for methylation datasets, we first converted these values into proportions
by applying the inverse-logit transformation. Since bi is a known offset in equation (2),
it was set equal to 0. The generated distances between the p probes mimicked the actual
distances in the GI cancer dataset, and they were then scaled to add to 1.
We considered four scenarios corresponding to the combinations of two noise levels and
two dependence levels. For each scenario, 20 datasets were generated, with each dataset
consisting of p = 500 probes and T = 5 treatments with 4 samples each, i.e., a total to
n = 20 samples. The low noise level corresponded to true variance parameter σ20 = 0.64;
equivalently, to a true signal-to-noise ratio (SNR) of approximately R20 = 0.7. The high noise
level corresponded to true variance parameter σ20 = 1.44; equivalently, to approximately
R20 = 0.4. The chosen between-probe dependences had two levels: no serial correlation (i.e.,
η0 = 0) and positive serial correlation of η0 = 0.004. For convenience, we shall refer to the
two dependence levels as “no correlation” and “high correlation,” respectively. Although
η0 = 0.004 may appear to be a small number, its value is calibrated to the inter-probe
distances. Specifically, when the distance between two adjacent probes is equal to the
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α1 α2 d2 β γ ρ µG τ
2
G τ
2

20 20 0.33 20 0.9 0.1 0 1 0.1225
Table 2: Parameters used for data generation of simulation study
standardized average distance of e¯ = 1/499, this value of η0 results in an affiliation of
r0 = 0.6 in equation (11). Since the affiliation is bounded above by 1, the value η0 = 0.004
represents fairly high serial correlation in the data.
Other parameter values used to generate the datasets were common across the four
scenarios. The values are displayed in Table 2. Each of the generated datasets contained
about 10% differential probes.
Detecting the absence or presence of serial correlation To assess the accuracy of
BayesDiff in detecting the underlying dependence structure, we focused on the following log-
Bayes factors. In the no-correlation (i.e., η0 = 0) situation, we considered log
(
P [η=0|X]
P [η>0|X]
)
. In
the high correlation (i.e., η0 = 004) situation, we considered log
(
P [η>0|X]
P [η=0|X]
)
. Thus, in each
situation, a large positive value for the corresponding log-Bayes factor would provide strong
evidence that the correct correlation level was detected by BayesDiff. Let Θ− denote all the
model parameters except η. In the high correlation situation, applying Jensen’s inequality, a
lower bound for the corresponding log-Bayes factor is found to be E
[
log
(
P [η>0|X,Θ−]
P [η=0|X,Θ−]
)
| X
]
.
Unlike log-Bayes factors, this lower bound can be estimated by an empirical average estimate
computed from a single MCMC run. In the no-correlation situation, a lower bound for the
corresponding log-Bayes factor can be similarly derived.
For each of the four generation scenarios, box plots of these estimated lower bounds for
the 20 datasets are depicted in Figure 3. The estimated lower bounds of the log-Bayes factors
in favor of the true correlation structure were all positive and sufficiently large. In both no-
correlation scenarios, BayesDiff favored zero order models. Although the estimates were
smaller in the no correlation–high noise scenario, the smallest lower bound among the 20
datasets was 7.0, corresponding to Bayes factors exceeding e7.0 = 1, 097. The 25th percentile
of these lower bounds was 15.7, corresponding to Bayes factors exceeding e15.7 = 6, 582, 993.
This is strong evidence that the BayesDiff approach is reliable in this scenario. For the
high-correlation scenarios, all the estimated lower bounds exceeded 50, corresponding to
Bayes factors exceeding e50 = 5.18× 1021. This shows that BayesDiff overwhelmingly favors
first order models when the data are, in fact, serially correlated.
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Figure 3: Box plots for the estimated lower bounds of the log-Bayes factors in favor of the
true model order in artificial datasets.
Comparisons with other methods We evaluated the success of the BayesDiff procedure
in detecting disease genomic signatures and made comparisons with six well-known proce-
dures. These included general statistical techniques for multigroup comparisons, namely,
one-way analysis of variance (ANOVA) and the Kruskal-Wallis test. We also made compar-
isons with some methods specially developed for detecting differential methylation in more
than two treatments: COHCAP (Warden et al. 2013), methylKit (Akalin et al. 2012), BiSeq
(Hebestreit et al. 2013), and RADMeth (Dolzhenko & Smith 2014).
The ANOVA and the Kruskal-Wallis test procedures were applied separately on each
probe. For the methods designed for methylation datasets, we first converted the gener-
ated continuous values into proportions by applying the inverse-logit transformation. The
transformed dataset was then analyzed by the COHCAP method. The remaining three
methylation-related methods are designed for bisulfite sequencing, which consists of the to-
tal methylation reads for each measured CpG site. For these methods, we further assumed
that there were 100 total reads for each probe, and so the methylation reads for each probe
was obtained by multiplying the proportion methylation values by the total reads. The
bandwidth smoothing parameter of the method BiSeq was tuned to optimize the overall
detection. For all six methods, the probe-specific p-values were obtained. The probes whose
test p-values were less than the desired significance level were labeled as differential for
that method.
We computed the receiver operating characteristic (ROC) curves for differential probe
detection for all seven methods. The ROC curves, averaged over the 20 datasets under each
simulation scenario, are shown in Figure 4. The individual ROC curve for each simulated
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dataset is available in Supplementary Materials. In all four scenarios, BayesDiff outperforms
the other methods, as indicated by the fact that the areas below the ROC curves are greater
for BayesDiff. As expected, all seven methods have lower accuracies for the higher noise
levels. The performance of BayesDiff is significantly better than the competing methods in
the high correlation scenarios, suggesting that the incorporation of between-probe depen-
dencies greatly improves its accuracy. For a quantitative assessment, we calculated the area
under curve (AUC) for the ROC curves, declaring the method as the most reliable when it
has the largest AUC in a given scenario. In addition, since researchers typically focus on
small false positive rates (FPRs), that is, small significance levels, we also calculated the
measures, AUC20 and AUC10. AUC20 (AUC10) is defined as the area under the ROC curve
multiplied by 5 (10) when the FPR does not exceed 0.2 (0.1). The multiplicative factor
ensures that the areas potentially vary between 0 and 1. The three versions of AUC are
presented in Table 3.
We find that BayesDiff has the largest AUC in every scenario, and furthermore, has vastly
improved reliability for low FPRs. For example, consider the low noise–high correlation
scenario. The overall AUC for BayesDiff is 0.073 greater than that for ANOVA. In contrast,
the gains for BayesDiff, relative to ANOVA, are +0.201 for AUC20 and +0.276 for AUC10.
The relative advantages of BayesDiff are even greater for the other competing methods.
These results demonstrate the ability of BayesDiff to accurately detect the differential probes
even in challenging situations where the FPR is small.
5 Data Analysis
We returned to the motivating DNA methylation dataset consisting of the four types
of GI cancer: stomach adenocarcinoma (STAD), liver hepatocellular carcinoma (LIHC),
esophageal carcinoma (ESCA) and pancreatic adenocarcinoma (PAAD). Applying the Bayes-
Diff procedure, we detected the differentially methylated CpG loci among the cancer types.
Data processing The dataset was obtained from The Cancer Genome Atlas project,
which is publicly available through The Genomic Data Commons (GDC) Data Portal (Gross-
man et al. 2016). The data are obtained from Illumina Human Methylation 450 platform
for each of 485,577 probes at CpG sites.
We picked a set of 443 genes involving mutation in at least 5% of the samples. We
randomly selected 50 samples from each cancer type, so that the number of samples under
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consideration, n = 50(4) = 200. The analysis was performed on a gene-by-gene basis. To
ensure that all CpG sites potentially related to a gene were included in the analysis, we
selected all sites located within 50K base pairs outside the gene body, specifically, upstream
from the 5’ end and downstream from the 3’ end. The number of gene-specific CpG sites
ranged from 1 to 769, and are displayed in Figure 5(a). As a final preprocessing step, we
eliminated the 25 genes mapped to 20 CpG sites or less. This was primarily because many
existing statistical methods are effective in genes for which the number of CpG sites, p, is
small, and also because the methylation patterns of short genes are usually of lesser interest
in cancer investigations.
Inference procedure The data were analyzed using the proposed BayesDiff approach.
Since DNA methylation data consist of proportions, the logit transformation was applied
in expression (1). The bi values in expression (2) were set equal to 0 because there are
no known subject-specific offsets. The MCMC procedure of Section 3.1 was applied to
obtain posterior samples for each gene. For detecting differentially methylated CpG sites,
we applied the Bayesian FDR control procedure of Section 3.2 with the desired FDR set at
q0 = 0.05.
Results For each gene, Figure 5(b) displays 95% credible intervals for lower bounds of
log-Bayes factors of a first versus zero order model, i.e., η = 0 versus η > 0 in expression
(11) for the inter-probe affiliations. Models with first order dependence are overwhelmingly
favored in a majority of the genes, suggesting that statistical techniques that do not account
for dependence between neighboring CpG sites would be less effective for these data.
Among the differentially methylated CpG sites detected by our approach, approximately
40.9% of the sites were located outside the gene bodies. Figure 6 displays the associations
between detected methylation status and positions of the CpG sites. For our analysis, we
have defined “near the 5’ (3’) end” as the CpG sites located within one-fourth length of the
gene body, either inside or outside the gene boundary, and closer to the transcription start
(termination) site. Our results indicate that the proportion of differential methylation is
higher for CpG sites inside the gene body, and that most differentially methylated loci are
situated within the gene body, as is well known from numerous previous studies. However,
our analysis also revealed significant amounts of differential methylation outside the gene
body. Despite the common belief that DNA methylation analysis should focus on the 5’
end region, we have found that CpG sites near the 3’ ends also display considerable degrees
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of differential methylation. These findings support the recommendations of Irizarry et al.
(2009) that the investigation of DNA methylation alteration should be conducted on a higher
resolution, epigenome-wide basis.
Among the differentially methylated sites detected by BayesDiff, we estimated the pair-
wise differences between the random effects associated with the four cancer types. Site-wise
summaries of the largest pairwise differences of the cancer-specific effects are plotted in Fig-
ure 7. None of the four cancer types displayed consistent hypermethylation or hypomethy-
lation across all the genes or across entire chromosomes. However, we found that LIHC is
frequently differentially methylated relative to one of the other cancer types, implying that
LIHC is the most volatile disease with respect to DNA methylation.
Figure 8 displays the detailed differential methylation pattern for the top two mutated
genes, TP53 and TTN. An obvious feature of both the genes is that the detected differen-
tial methylation of the CpG sites is highly serially correlated. For gene TP53, none of the
differentially methylated loci is within the gene body. The 3’ end region outside the gene
body has a cluster of differentially methylated loci, for which cancer type STAD is mostly
hypermethylated. The results for gene TTN tell a quite different story: most of the differ-
entially methylated loci are inside the gene body and near the 5’ end. Cancer type LIHC
is hypomethylated compared to PAAD around the 5’ end region, but it is hypermethylated
compared to STAD near the 3’ end.
Finally, a set of genes with at least 90% of the sites differentially methylated is listed in
Table 4. For these genes, the conditional proportion of differentially methylated sites inside
the gene body, outside the gene body, near the 5’ end, and near the 3’ end, have been are
displayed. Also displayed are the largest pairwise differences of the cancer types among the
detected differentially methylated loci. The actual number of CpG sites within each segment
is listed in Supplementary Materials.
Existing medical literature supports several of our findings. For example, gene FBN2
was shown to be hypermethylated in esophageal squamous cell carcinoma (ESCA) (Tsunoda
et al. 2009). Gene DCC is also hypermathylated, supporting its role as a tumor suppressor
gene in ESCA (Lui Park et al. 2008). The low expression of gene LAMA2 is associated
with poor survival outcomes and high recurrence rates of cancer type LIHC (Jhunjhunwala
et al. 2014); our results reveal the hypomethylation of gene LAMA2 in cancer types LIHC
versus PAAD.
Our findings also complement the conclusions of other medical studies. While various
studies have found that the gene and protein expressions of ABC transporter genes, such as
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ABCC9, are useful for understanding the prognosis of esophageal cancer (Vrana et al. 2018),
we find that the hypermethylation of ABCC9 is a major difference between the cancer types,
ESCA and LIHC. Gene LRT2 is a potential tumor suppressor that is hypermethylated and
downregulated in breast cancer (Bae et al. 2017). Our results indicate that this gene is also
hypermethylated in cancer type STAD versus LIHC.
6 Discussion
DNA methylation data in GI cancer, like many other kinds of ’omics data, exhibit complex
structures due to unknown biological mechanisms and distance-dependent serial correlations
among neighboring probes. The identification of differential signatures among different
groups of samples is crucial for developing targeted treatments for disease.
This paper formulates a flexible Bayesian approach that is called BayesDiff, applicable to
’omics datasets of different sizes and scales, and to multiple sample groups. The techniques
relies on a novel first order mixture model called the Sticky Poisson-Dirichlet process or
the multicuisine restaurant franchise. In addition to allowing for simultaneous inferences on
the probes, the model accommodates distance-based serial dependence and account for the
complex interaction patterns of cancer data. The Sticky PDP model encompasses several
well-known Bayesian mixture models in the literature.
The success of the BayesDiff procedure in differential DNA methylation, relative to well-
established strategies, is exhibited via simulation studies. The new technique is applied to
the motivating TCGA dataset to detect the differential genomic signature for four types of
upper GI cancer. The results both support and complement various known features and gene
associations of differential methylation in cancer. It also reveals a set of genes exhibiting high
proportions of differential methylation among the four cancer types. These results emphasize
the need for further investigation to better understand the molecular characterizations of
upper GI cancer.
Ongoing work involves extending the correlation structure in several types of datasets
that necessitate incorporating more sophisticated forms of dependence. Equation (1) makes
a platform-specific, deterministic global transformation and imposes a Gaussian mixture
model on the transformed data. Due to the flexibility of Bayesian nonparametric models,
this construction is likely to be adequate. However, we expect much greater dimension
reduction in the large number of probes via probabilistic frameworks such as the Conway-
Maxwell-Poisson distribution for overdispersed or underdispersed count data, logistic model
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Figure 4: ROC curves, averaged over 20 simulated datasets, for the seven methods under
the four simulation scenarios.
for binary data, and probit model for proportion data. These extensions will be the focus
of future papers.
We are currently developing an R package implementing BayesDiff in a parallel com-
puting framework using graphical processing units. The software will be made available
for detecting differential genomic signatures in wide variety of applications. Initial results
indicate that dramatic speedups of several orders of magnitude would allow the analysis of
user-specified datasets on ordinary personal computers.
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Low noise High noise
High correlation No correlation High correlation No correlation
AUC
BayesDiff 0.990 0.963 0.945 0.921
ANOVA 0.916 0.941 0.862 0.897
Kruskal-Wallis 0.912 0.934 0.860 0.890
COHCAP 0.916 0.940 0.861 0.895
Methylkit 0.912 0.936 0.854 0.887
BiSeq 0.910 0.932 0.857 0.891
RADMeth 0.917 0.940 0.863 0.898
AUC20
BayesDiff 0.977 0.910 0.883 0.797
ANOVA 0.776 0.821 0.614 0.697
Kruskal-Wallis 0.758 0.800 0.599 0.672
COHCAP 0.774 0.821 0.617 0.689
Methylkit 0.756 0.802 0.600 0.667
BiSeq 0.732 0.773 0.594 0.660
RADMeth 0.769 0.816 0.613 0.692
AUC10
BayesDiff 0.969 0.883 0.854 0.741
ANOVA 0.693 0.753 0.519 0.595
Kruskal-Wallis 0.673 0.731 0.487 0.569
COHCAP 0.686 0.753 0.518 0.580
Methylkit 0.656 0.721 0.482 0.548
BiSeq 0.608 0.661 0.469 0.536
RADMeth 0.686 0.744 0.506 0.583
Table 3: Areas under ROC curves for the different methods (rows) under the four simulation
scenarios (columns). See the text for further discussion.
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(b) 95% credible intervals for lower bounds of
log-Bayes factors of first order versus zero order
models. The intervals whose lower limits are
positive are marked in red.
Figure 5: Data analysis plots. See the Section 5 text for further explanation.
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(a) Contingency table of detected methylation sta-
tus and location of CpG site with respect to gene
body
(b) Contingency table of detected methylation sta-
tus and proximity of CpG site to chromosomal end
Figure 6: Associations of detected methylation status and positions of CpG sites.
Figure 7: Site-wise summary of the largest pairwise differences of differentially methylated
loci among the four cancer types
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Figure 8: Detailed differential methylation results for the top 2 mutated genes. For each
gene, the upper panel shows the mean methylation levels. The middle panel shows the pos-
terior probabilities of each CpG site being differentially methylated, with solid points rep-
resenting differential methylation and dashed line denoting the corresponding cutoff value.
The lower panel indicates the largest pairwise difference between the 4 cancer types. Sym-
bols 1–4 in the lower panel represent GI cancer types STAD, LIHC, ESCA and PAAD,
respectively. The vertical dotted lines represent the gene boundaries. The arrow at the top
indicates the transcription direction.
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Gene name Overall
Inside Outside Near Near Largest
gene body gene body 5’ end 3’ end difference
ABCC9 1.000 1.000 1.000 1.000 1.000 ESCA↑ LIHC↓
FBN2 1.000 1.000 1.000 1.000 1.000 ESCA↑ LIHC↓
SPHKAP 1.000 1.000 1.000 1.000 1.000 ESCA↑ LIHC↓
UNC13C 1.000 1.000 1.000 1.000 1.000 STAD↑ PAAD↓
XIRP2 1.000 1.000 1.000 1.000 1.000 PAAD↑ LIHC↓
ZNF804B 1.000 1.000 1.000 1.000 N/A STAD↑ LIHC↓
LAMA2 0.971 0.966 1.000 1.000 0.667 PAAD↑ LIHC↓
PREX2 0.952 1.000 0.857 0.950 N/A STAD↑ LIHC↓
TSHZ3 0.949 0.875 0.968 1.000 0.750 STAD↑ LIHC↓
DCC 0.943 0.941 0.944 1.000 0.333 ESCA↑ LIHC↓
CDH8 0.923 0.920 1.000 1.000 N/A STAD↑ LIHC↓
FLRT2 0.922 0.900 1.000 1.000 0.800 STAD↑ PAAD↓
Table 4: Genes with the overall proportion of differentially methylated CpG sites exceeding
0.9, listed in descending order. The middle panel of columns lists the conditional proportion
of differential methylation for different segments of the site locations. For genes ZNF804B,
PREX2 and CDH8, no sites were located within the 3’ end. The rightmost column displays
which pair-wise difference between the four cancer types is the largest, with the symbol “↑
(↓)” indicating higher (lower) methylation level for one cancer type relative to the other.
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